TY - JOUR T1 - Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) JF - medRxiv DO - 10.1101/2020.11.08.20227876 SP - 2020.11.08.20227876 AU - Daniel D. Murray AU - Abdel G. Babiker AU - Jason V. Baker AU - Christina E. Barkauskas AU - Samuel M. Brown AU - Christina C. Chang AU - Victoria J. Davey AU - Annetine C. Gelijns AU - Adit A. Ginde AU - Birgit Grund AU - Elizabeth Higgs AU - Fleur Hudson AU - Virginia L. Kan AU - H. Clifford Lane AU - Thomas A. Murray AU - Roger Paredes AU - Mahesh K.B. Parmar AU - Sarah Pett AU - Andrew N. Phillips AU - Mark N. Polizzotto AU - Cavan Reilly AU - Uriel Sandkovsky AU - Shweta Sharma AU - Marc Teitelbaum AU - B. Taylor Thompson AU - Barnaby E. Young AU - James D. Neaton AU - Jens D. Lundgren AU - on behalf of the TICO Study Group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/08/2020.11.08.20227876.abstract N2 - Background Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership initiated the Therapeutics for Inpatients with COVID-19 (TICO). TICO is a multi-arm, multi-stage (MAMS) platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of novel candidate anti-viral therapeutic agents for adults hospitalized with COVID-19. Four agents have so far entered the protocol, with rapid answers already provided for three of these. Other agents are expected to enter the protocol throughout 2021. This protocol contains a number of key design and implementation features that, along with challenges faced by the protocol team, are presented and discussed.Protocol Design and Implementation Three clinical trial networks, encompassing a global network of clinical sites, participated in the protocol development and implementation. TICO utilizes a MAMS design with an agile and robust approach to futility and safety evaluation at 300 patients enrolled, with subsequent expansion to full sample size and an expanded target population if the agent shows an acceptable safety profile and evidence of efficacy. Rapid recruitment to multiple agents is enabled through the sharing of placebo as well as the confining of agent-specific information to protocol appendices, and modular consent forms. In collaboration with the Food and Drug Administration, a thorough safety data collection and DSMB schedule was developed for the study of agents with limited in-human data.Challenges Challenges included ensuring drug supply and reliable recruitment allowing for changing infection rates across the global network of sites, the need to balance the collection of data and samples without overburdening clinical staff, and obtaining regulatory approvals across a global network of sites.Conclusion Through a robust multi-network partnership, the TICO protocol has been successfully used across a global network of sites for rapid generation of efficacy data on multiple novel antiviral agents. The protocol design and implementation features used in this protocol, and the approaches to address challenges, will have broader applicability. Mechanisms to facilitate improved communication and harmonization among country-specific regulatory bodies are required.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04501978Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04501978?term=NCT04501978&draw=2&rank=1 Funding StatementTICO is funded primarily through Operation Warp Speed (now White House COVID-19 Response Team) sub-contracted through Leidos Biomedical Research Inc.. Additional funding was provided by the NIH (including NHLBI, NIAID), U.S. Department of Veterans Affairs, as well as the governments of Denmark (National Research Foundation; grant no 126), Australia (National Health and Medical Research Council), and U.K. (Medical Research Council, MRC_UU_12023/23).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Central IRB approval in the U.S. was recieved from Advarra (IORG 0000635 and IRB reg number 00000971). All countries and local sites that will participate in this study are also required to gain approval from relevant local bodies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no data relevant to this manuscript ER -